4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Current Deferred Revenue of $360000.0 for Q1 2026, down 58.43% year-over-year from $866000.0 in Q1 2025, and little changed quarter-over-quarter from $360000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Current Deferred Revenue data on file, last reported at $360000.0 in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $360000.0, down 58.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $360000.0 (down 58.43% YoY), and the FY2025 annual result was $360000.0, up 40.08% from the prior year.
- Current Deferred Revenue was little changed at $360000.0 in Q1 2026 per FDMT's latest filing, from $360000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $3.9 million in Q1 2022 and troughed at $35000.0 in Q3 2024.
- A 5-year average of $1.2 million and a median of $778000.0 in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue tumbled 97.15% in 2024, then surged 928.57% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $2.0 million in 2022, then tumbled by 86.07% to $273000.0 in 2023, then dropped by 5.86% to $257000.0 in 2024, then jumped by 40.08% to $360000.0 in 2025, then changed by 0.0% to $360000.0 in 2026.
- Business Quant data shows FDMT's Current Deferred Revenue at $360000.0 in Q1 2026, $360000.0 in Q4 2025, and $360000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 360,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | 257,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 1.23 Mn |
| Jun 30, 2023 | 576,000.00 |
| Mar 31, 2023 | 778,000.00 |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 3.21 Mn |
| Jun 30, 2022 | 2.26 Mn |
| Mar 31, 2022 | 3.87 Mn |
| Dec 31, 2021 | 5.09 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Jun 30, 2021 | 3.02 Mn |
| Mar 31, 2021 | 7.09 Mn |
| Dec 31, 2020 | 19.81 Mn |